Jubilant Pharmova Ltd Share Price
As on 18 November 2025 at 23:55 IST
Jubilant Pharmova Ltd. Q1 FY26 Results:
Net profit for the period declined 79% to ₹103 crores in Q1 FY26, from ₹482 crores in Q1 FY25. Total income for the quarter increased 10% year-on-year to ₹1,913 crores, from ₹1,746 crores.
About Jubilant Pharmova Ltd
Jubilant Pharmova Ltd is a global integrated pharmaceutical and life sciences company. Founded in 1978, it has transformed from a small chemical manufacturer to a global pharmaceutical player under the Bhartia family's leadership. The company is headquartered in Uttar Pradesh, India. It specializes in allergy therapy products, sterile injectables, and Active Pharmaceutical Ingredients (APIs). Through its subsidiary Jubilant Biosys, it provides contract research and development services. Operating in the pharmaceutical and life sciences sector, the company has established itself as a significant player in specific segments like radiopharmaceuticals in North America. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
7.33%
Over 6 Months
20.71%
Over 1 Year
1.18%
Over 3 Years
205.54%
Jubilant Pharmova Ltd Summary
Close ₹1,158.90
Open ₹1,149
High ₹1,162
Low ₹1,133.50
Volume 1,74,708
Net Turnover (in Cr) ₹20.11
52Wk High ₹1,265
52Wk Low ₹802
52Wk High / Low
802
1,265
Jubilant Pharmova Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹18,461.28
EPS (TTM) -
Book Value (BV) 140.87
Div. Yield 0.43 %
P/E (TTM) 1,007.61
Price/Book Value 8.23
Delivery % 61.40 %
Face Value 1
Key Ratios
PE Ratio 737.77
PB Ratio 6.12
EV to Sales 19.50
PEG Ratio -18.82
ROA 0.72
ROE 1.04
Debt-Equity 0.15
Net Profit Margin 3.29
Operating Profit Margin 17.66
Jubilant Pharmova Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 7,291.30 | 6,771.60 | 6,320 | 6,141.45 | 6,116.17 |
| Total Expenses | 6,669.70 | 6,456.30 | 6,247.70 | 5,501.02 | 5,235.12 |
| Profit Before Tax | 980.60 | 170.50 | 27.80 | 630.45 | 871.08 |
| Profit After Tax | 836.30 | 72.70 | -64.90 | 413.02 | 573.86 |
| Operating Profit After Depreciation | 861.90 | 587.60 | 260.50 | 785.92 | 1,065.15 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 6,091.20 | 5,942 | 5,971.50 | 5,668.35 | 5,227.96 |
| Total Non Current Assets | 9,179.20 | 7,672.40 | 7,394.30 | 6,481.68 | 5,965.61 |
| Total Current Assets | 3,577.20 | 3,876.10 | 3,762.40 | 3,509.19 | 2,952.50 |
| Total Assets | 12,756.40 | 11,548.50 | 11,156.70 | 9,990.87 | 8,918.11 |
| Total Shareholder's Fund | 6,254.90 | 5,433.90 | 5,399.30 | 5,318.56 | 4,741.49 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,072.10 | 971.30 | 660.70 | 837.54 | 1,784.27 |
| Net Cash Used In Investing Activities | 512.50 | -596.30 | -473.90 | -323.08 | -726.76 |
| Net Cash Used In Financing Activities | -1,452.70 | -432.50 | -156.70 | -32.60 | -1,709.39 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 845.30 | 888.10 | 948 | 851.89 | 2,757.38 |
| Total Expenses | 796.50 | 846.40 | 868.70 | 767.17 | 2,484.21 |
| Profit Before Tax | 37.60 | 41.70 | 79.30 | 84.72 | 273.17 |
| Profit After Tax | 19.20 | 31.60 | 49.90 | 80.49 | 214.47 |
| Operating Profit After Depreciation | 78.60 | 71.60 | 97.80 | 95.71 | 374.97 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 698.70 | 711.30 | 687.40 | 636.51 | 127.08 |
| Total Non Current Assets | 2,425.40 | 2,451.30 | 2,429.60 | 2,369.75 | 1,778.35 |
| Total Current Assets | 484.20 | 540.60 | 578.80 | 525.81 | 66.25 |
| Total Assets | 2,909.60 | 2,991.90 | 3,008.40 | 2,895.56 | 1,844.60 |
| Total Shareholder's Fund | 2,318.10 | 2,374.50 | 2,414.50 | 2,439.07 | 1,282.44 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 135.60 | 143.20 | -65.10 | -3.55 | 608.38 |
| Net Cash Used In Investing Activities | -2.30 | -40.30 | 31.10 | 93.10 | 177.96 |
| Net Cash Used In Financing Activities | -156.80 | -77.80 | 22.50 | -107.37 | -781.65 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,966.40 | 1,900.70 | 1,928.80 | 1,821.70 | 1,752.30 |
| Total Expenses | 1,625.10 | 1,611.20 | 1,583.50 | 1,534.60 | 1,463 |
| Profit Before Tax | 190.30 | 154.40 | 206 | 130.50 | 144.40 |
| Profit After Tax | 119.90 | 102.50 | 151.30 | 100.70 | 102.50 |
| Operating Profit after Depreciation | 351.10 | 301.50 | 357.20 | 296.30 | 311 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 66.40 | 59.50 | 60.70 | 196 | 61.40 |
| Total Expenses | 54.60 | 49.20 | 49.80 | 185 | 55.20 |
| Profit Before Tax | 50.10 | 8.20 | 19.30 | 8.70 | 20.80 |
| Profit After Tax | -6.40 | 5.80 | 13.60 | 5.30 | 10.50 |
| Operating Profit after Depreciation | 54.20 | 12.70 | 23.90 | 29.40 | 25.70 |
Jubilant Pharmova Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,140.93
S2 1,122.97
S3 1,112.43
Pivot 1,151.47
R1 1,169.43
R2 1,179.97
R3 1,197.93
Moving Average
20 SMA 1,130.96
50 SMA 1,110
100 SMA 1,125.05
200 SMA 1,048.57
Jubilant Pharmova Ltd Corporate Actions
Jubilant Pharmova Ltd
₹5.0/Share
Announcement Date 25 Jul 2025
Record Date 25 Jul 2025
Div Yield 500%
Jubilant Pharmova Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
Jubilant Pharmova Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Bandhan Focused Fund | 4.19% |
| Kotak Special Opportunites Fund | 3.85% |
| Kotak MNC Fund | 1.80% |
| HDFC Pharma and Healthcare Fund | 1.78% |
| Kotak Contra Fund | 1.29% |
Jubilant Pharmova Ltd News
Board of Jubilant Pharmova approves grant of 1,506 stock options
At meeting held on 31 October 2025
31 Oct 2025, 02:44 pm
Jubilant Pharmova to discuss results
On 31 October 2025
15 Oct 2025, 09:34 am
Jubilant HollisterStier expands its sterile injectable manufacturing capacity at Spokane unit in the US
10 Oct 2025, 09:51 am
Jubilant Pharmova appoints Arun Kumar Sharma as CFO
Jubilant Pharmova's board approved the appointment of Arun Kumar Sharma as a chief financial officer (CFO) with effect from 1st October 2025.
23 Sep 2025, 12:39 pm
Jubilant Pharmova's step-down subsidiary completes US FDA audit with no observations
Jubilant Pharmova has announced completion of the United States Food and Drug Administration (US FDA) post-marketing adverse drug experience (PADE) inspection of Jubilant Cadista Pharmaceuticals Inc, USA.
22 Sep 2025, 10:01 am
Jubilant Pharmova Ltd Stock Analysis
- Annual revenue for Jubilant Pharmova Ltd decreased by 4.82% to ₹845.30 crore in FY 2025 from ₹888.10 crore in FY 2024.
- Annual Net Profit for Jubilant Pharmova Ltd decreased by 39.24% to ₹19.20 crore in FY 2025 from ₹31.60 crore in FY 2024.
- Promoter Shareholding in Jubilant Pharmova Ltd remains unchanged by 0.00% in the most recent quarter, from 47.68% in June 2025 to 47.68% in September 2025.
- Jubilant Pharmova Ltd delivered a 1-year return of 1.18% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Jubilant Pharmova Ltd share price moved down by 1.37% from its previous close of INR ₹1,158.90. The latest Jubilant Pharmova Ltd share price is INR ₹1,143.
- Jubilant Pharmova Ltd share price today has been at a low of 1,132.20 and a high of 1,160.80. Over the past 52 weeks, the Jubilant Pharmova Ltd share price has seen a low of 802 and a high of 1,265.
About Jubilant Pharmova Ltd
Jubilant Pharmova Ltd. (formerly Jubilant Life Sciences) is a global integrated pharmaceutical and life sciences company. The company operates in the pharmaceutical and life sciences sectors. It focuses on pharmaceutical manufacturing, contract research, and drug discovery services.
Established in 1978, the company has over many decades of experience in the pharmaceutical industry. The company's headquarters is located in Uttar Pradesh, India.
The company is promoted by the Bhartia family. Shyam S. Bhartia serves as Chairman, and Hari S. Bhartia is Co-Chairman and Managing Director. The Bhartia family has been instrumental in transforming the company from a small chemical manufacturer to a global pharmaceutical player. The other crucial managerial promoters of the company include:
Jubilant Pharmova is a significant player in the pharmaceutical sector. However, it is not the #1 company in terms of market capitalization or market share in India's pharmaceutical sector. The company has established itself as one of the leading players in specific segments like radiopharmaceuticals in North America. The promoter shareholding in the company stands at 50.68%. This indicates strong promoter confidence in the business.
The company's registered office is located at Bhartiagram, Gajraula, Amroha Dist., Uttar Pradesh - 244223, India. KFin Technologies Limited serves as the Registrar and Transfer Agent. The company's board comprises a mix of executive and independent directors, ensuring proper corporate governance.
The company's influence is reflected in its organizational structure and leadership approach. Under the guidance of Chairman Shyam S. Bhartia, Jubilant Pharmova has cultivated a culture of innovation and excellence. The substantial promoter shareholding has proven to be a crucial factor in maintaining stable leadership and enabling long-term strategic planning. This strong promoter backing has allowed the company to make bold decisions and investments in emerging pharmaceutical segments. This contributes to its sustained growth and influence in the industry.
In the sector of specialized pharmaceuticals, Jubilant Pharmova has carved out a distinctive niche. Their radiopharmaceutical division has become particularly influential in North America. At this place, they have established themselves as a key player in nuclear medicine. This achievement is significant as it demonstrates an Indian company's ability to succeed in highly regulated and technologically advanced markets. Their expertise in allergy therapy products and sterile injectables manufacturing has made them a preferred partner for global pharmaceutical companies. This further enhances India's reputation in the global pharmaceutical supply chain.
The company's Active Pharmaceutical Ingredients (APIs) business has played a crucial role in strengthening India's position as the 'pharmacy of the world.' By ensuring a reliable supply of high-quality APIs, Jubilant Pharmova has contributed to the security and stability of global pharmaceutical supply chains. In this factor, it gained particular significance during global health crises. This has helped establish India's credibility as a dependable source of pharmaceutical products and ingredients.
Through their subsidiary Jubilant Biosys, the company has made substantial contributions to pharmaceutical research and development. Their contract research services have been instrumental in accelerating drug discovery. Also, their research helped various pharmaceutical companies improve their development processes. This has not only generated revenue but has also positioned India as a hub for pharmaceutical research and development, attracting international collaboration and investment.
The company's influence extends to corporate governance and management practices. Their professional management team has set high standards for corporate governance in the Indian pharmaceutical sector. This has helped build trust among international partners and investors, facilitating global expansion and partnerships.
The influence of Jubilant Pharmova is also evident in its commitment to sustainability and social responsibility. Their business practices have demonstrated that pharmaceutical companies can balance profitability with environmental and social considerations. This sets an example for other companies in the sector.
The company's journey from a chemical manufacturer to a global pharmaceutical player serves as an inspiration for emerging pharmaceutical companies, particularly in developing nations. Jubilant Pharmova continues to shape the pharmaceutical industry's future. This is done through its diverse operations, strong leadership, commitment to innovation, and adherence to high standards of corporate governance. The company's success story contributes to India's pharmaceutical prowess. Also, this demonstrates how pharmaceutical companies can evolve and adapt to meet changing global healthcare needs while maintaining ethical business practices. As the pharmaceutical industry continues to evolve, Jubilant Pharmova's influence is likely to grow. This further solidifies its position as a respected player in the global pharmaceutical and life sciences sector.
Established in 1978, the company has over many decades of experience in the pharmaceutical industry. The company's headquarters is located in Uttar Pradesh, India.
The company is promoted by the Bhartia family. Shyam S. Bhartia serves as Chairman, and Hari S. Bhartia is Co-Chairman and Managing Director. The Bhartia family has been instrumental in transforming the company from a small chemical manufacturer to a global pharmaceutical player. The other crucial managerial promoters of the company include:
- Priyavrat Bhartia
- Arjun Shanker Bhartia
- Arvind Chokhany
Jubilant Pharmova is a significant player in the pharmaceutical sector. However, it is not the #1 company in terms of market capitalization or market share in India's pharmaceutical sector. The company has established itself as one of the leading players in specific segments like radiopharmaceuticals in North America. The promoter shareholding in the company stands at 50.68%. This indicates strong promoter confidence in the business.
The company's registered office is located at Bhartiagram, Gajraula, Amroha Dist., Uttar Pradesh - 244223, India. KFin Technologies Limited serves as the Registrar and Transfer Agent. The company's board comprises a mix of executive and independent directors, ensuring proper corporate governance.
Influence of the Company
Jubilant Pharmova Ltd. stands as a testament to India's growing prominence in the global pharmaceutical landscape. Since its establishment in 1978, the company has undergone a remarkable transformation from a modest chemical manufacturer to a multinational pharmaceutical and life sciences organization. The evolution was steered by the visionary leadership of the Bhartia family. This represents corporate success and India's capability to compete and excel in the global pharmaceutical arena. The company's journey reflects the dynamic nature of the pharmaceutical industry and demonstrates how strategic leadership can drive sustainable growth and innovation.The company's influence is reflected in its organizational structure and leadership approach. Under the guidance of Chairman Shyam S. Bhartia, Jubilant Pharmova has cultivated a culture of innovation and excellence. The substantial promoter shareholding has proven to be a crucial factor in maintaining stable leadership and enabling long-term strategic planning. This strong promoter backing has allowed the company to make bold decisions and investments in emerging pharmaceutical segments. This contributes to its sustained growth and influence in the industry.
In the sector of specialized pharmaceuticals, Jubilant Pharmova has carved out a distinctive niche. Their radiopharmaceutical division has become particularly influential in North America. At this place, they have established themselves as a key player in nuclear medicine. This achievement is significant as it demonstrates an Indian company's ability to succeed in highly regulated and technologically advanced markets. Their expertise in allergy therapy products and sterile injectables manufacturing has made them a preferred partner for global pharmaceutical companies. This further enhances India's reputation in the global pharmaceutical supply chain.
The company's Active Pharmaceutical Ingredients (APIs) business has played a crucial role in strengthening India's position as the 'pharmacy of the world.' By ensuring a reliable supply of high-quality APIs, Jubilant Pharmova has contributed to the security and stability of global pharmaceutical supply chains. In this factor, it gained particular significance during global health crises. This has helped establish India's credibility as a dependable source of pharmaceutical products and ingredients.
Through their subsidiary Jubilant Biosys, the company has made substantial contributions to pharmaceutical research and development. Their contract research services have been instrumental in accelerating drug discovery. Also, their research helped various pharmaceutical companies improve their development processes. This has not only generated revenue but has also positioned India as a hub for pharmaceutical research and development, attracting international collaboration and investment.
The company's influence extends to corporate governance and management practices. Their professional management team has set high standards for corporate governance in the Indian pharmaceutical sector. This has helped build trust among international partners and investors, facilitating global expansion and partnerships.
The influence of Jubilant Pharmova is also evident in its commitment to sustainability and social responsibility. Their business practices have demonstrated that pharmaceutical companies can balance profitability with environmental and social considerations. This sets an example for other companies in the sector.
The company's journey from a chemical manufacturer to a global pharmaceutical player serves as an inspiration for emerging pharmaceutical companies, particularly in developing nations. Jubilant Pharmova continues to shape the pharmaceutical industry's future. This is done through its diverse operations, strong leadership, commitment to innovation, and adherence to high standards of corporate governance. The company's success story contributes to India's pharmaceutical prowess. Also, this demonstrates how pharmaceutical companies can evolve and adapt to meet changing global healthcare needs while maintaining ethical business practices. As the pharmaceutical industry continues to evolve, Jubilant Pharmova's influence is likely to grow. This further solidifies its position as a respected player in the global pharmaceutical and life sciences sector.
FAQ’s
What is the share price of Jubilant Pharmova Ltd today?
Jubilant Pharmova Ltd share price as on 18 Nov 2025 is ₹ 1143.0
What is the Market Cap of Jubilant Pharmova Ltd?
The market cap of Jubilant Pharmova Ltd stock is ₹18,461.28 Cr.
What is the PE Ratio of Jubilant Pharmova Ltd?
The Price to Earnings (P/E) Ratio of Jubilant Pharmova Ltd is 737.77
What is the PB Ratio of Jubilant Pharmova Ltd?
The Price to Book (P/B) Ratio of Jubilant Pharmova Ltd is 6.12
What is the 52 week high of Jubilant Pharmova Ltd Share Price?
The 52 week high of Jubilant Pharmova Ltd share price stands at ₹1,265
What is the 52 week low of Jubilant Pharmova Ltd Share Price?
The 52 week low of Jubilant Pharmova Ltd share price stands at ₹802
How can I buy shares of Jubilant Pharmova Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Jubilant Pharmova Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
